Avinger INC

Avinger, Inc. has entered into a general assignment for the benefit of creditors, resulting in the termination of key executives and resignations of board members.

Avinger, Inc. stockholders have approved a proposal for assignment for the benefit of creditors followed by a voluntary dissolution and liquidation, contingent on the board's assessment of the best interests of the company and its stockholders.

Avinger Inc.'s special stockholder meeting was adjourned due to a lack of quorum and will reconvene on February 5, 2025.

Avinger, Inc. is shifting its focus from peripheral artery disease (PAD) to coronary artery disease (CAD) treatment, resulting in the termination of 36 employees and the cessation of PAD product manufacturing.

Avinger, Inc. declared and paid dividends in the form of preferred stock and increased the designated number of Series F preferred shares.

Avinger Inc. held its 2024 Annual Meeting where stockholders approved an amended equity incentive plan, elected directors, and ratified the appointment of an independent accounting firm.

Avinger Inc. announced its Q3 2024 financial results, highlighting a strategic realignment and cost reduction plan, alongside ongoing efforts to secure financial stability.

Avinger Inc. announced its Q2 2024 financial results, highlighting a strategic realignment and cost reduction plan, alongside ongoing efforts to secure financial stability.

Avinger Inc. announces its Q1 2024 financial results, highlighting a strategic collaboration with Zylox-Tonbridge and a private placement.

Avinger Inc.'s 10-K filing reveals a challenging financial year with strategic moves including a new partnership and financing.

Nabeel Subainati, Vice President of Finance at Avinger Inc., sold 1,255 shares of common stock to cover tax obligations related to vesting of RSUs.

Avinger Inc.'s CEO, Jeffrey M. Soinski, sold 3,690 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Avinger Inc.'s Chief Technology Officer, Himanshu Patel, sold 2,215 shares of common stock to cover tax obligations related to vesting RSUs.

Avinger, Inc. has adjourned its Special Meeting of Shareholders from January 24, 2025, to February 5, 2025.

Avinger, Inc. has amended its proxy statement to clarify the voting requirements for proposals at the upcoming special meeting on January 24, 2025.

Avinger, Inc. is contacting stockholders to encourage them to vote on a proposal to approve a voluntary dissolution and liquidation plan at a Special Meeting on January 24, 2025.

Avinger, Inc. is seeking stockholder approval for an assignment for the benefit of creditors followed by a voluntary dissolution and liquidation due to ongoing financial challenges.

Avinger, Inc. has filed a definitive proxy statement with the SEC.

Avinger, Inc. is holding its 2024 annual meeting of stockholders to elect directors, ratify the appointment of its accounting firm, approve executive compensation, and amend its equity incentive plan.

Avinger, Inc. announces a proposed offering of common stock and warrants to raise approximately $5.3 million for working capital and general corporate purposes.

Avinger, Inc. files an amendment to its registration statement for a proposed offering of common stock and warrants to raise capital for working capital and general corporate purposes.

Avinger, Inc. files for a potential offering of common stock and warrants to bolster working capital and general corporate purposes.